Aravax appoints Dr Brett Haumann to Board of Directors

6 May 2022/by Admin

Aravax opens IND for PVX108 Phase 2 trials and strengthens SAB

3 March 2022/by Admin

Aravax appoints Principal Investigators for PVX108 Phase 2 trials in United States and Australia

27 August 2021/by Admin

Aravax presents PVX108 Phase 1 longitudinal immunology data at EAACI 2021

13 July 2021/by Admin

Aravax appoints Financial Executive Thomas Ulmer to Board of Directors

1 November 2020/by Admin

Aravax receives positive pre-IND feedback from FDA on PVX108 Phase 2 trial plans

30 September 2019/by Admin

Aravax Presents Additional Positive PVX108 Phase 1 Clinical Trial Safety Results at EAACI 2019

4 June 2019/by Admin

Aravax to Present Additional PVX108 Phase 1 Clinical Trial Safety Results at EAACI 2019

28 May 2019/by Admin

Australian peanut therapy developer Aravax reveals positive Phase I trial results at AAAAI

25 February 2019/by Admin

Aravax to Present PVX108 Phase 1 Clinical Trial Results at AAAAI 2019 Annual Meeting

13 February 2019/by Admin

Aravax receives $1.9 million investment tranche from the Medical Research Commercialisation Fund

2 May 2018/by Admin

Collaborator of Aravax, the Benaroya Research Institute, receives $5 million grant

29 January 2018/by Admin